• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca, Shenzhen University Health Science Center to collaborate

AstraZeneca, Shenzhen University Health Science Center to collaborate

March 31, 2014
CenterWatch Staff

AstraZeneca has announced a research collaboration with Shenzhen University Health Science Center. The partners will undertake preclinical research focused on chronic kidney disease (CKD), which represents a large and growing unmet medical need in China.

In 2010, there were over 112 million kidney disease sufferers in China and this number is expected to rise 20% to more than 135 million by 2025.

Scientists from Shenzhen University Health Science Center's Nephrology and Urology Center will work in collaboration with teams from AstraZeneca's Innovation Center China in Shanghai, bringing together complementary skills to harness and foster medical innovation: Shenzhen University's academic and clinical capabilities and AstraZeneca's global research and drug discovery. Financial details of the agreement have not been disclosed.

The partners will focus on diabetic nephropathy, damage to the kidneys caused by diabetes which, in severe cases, can lead to kidney failure. While not all diabetes patients have kidney damage, it is growing at exponential rates in China. Between 2010 and 2025, the number of patients who experience kidney failure as a result of diabetic complications is expected to increase nearly 80% in China, to over 18 million patients. China has overtaken the U.S. in the prevalence of diabetes, with nearly 114 million Chinese citizens, or 11.5% of all adults, living with the disease in 2010.

"This collaboration signifies an expansion into an important new disease area for AstraZeneca's drug discovery efforts here in China," said Steve Yang, vice president and head of the company's Asia and Emerging Markets Innovative Medicines Unit. "Last year, we delivered the first AstraZeneca preclinical candidate drug to be discovered by our scientists in China, in oncology. And now, in addition to our ongoing research efforts in oncology, we also are putting our talented scientists to work in CKD—another area of unmet medical need. This demonstrates our commitment to R&D in China through both internal capability building and external partnerships."

He added that this partnership builds on AstraZeneca's strategic collaboration with Fibrogen, announced in July last year to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of with CKD and end-stage renal disease (ESRD) in key markets around the world, including China.

Xiaolin Zhang, head of AstraZeneca's Innovation Center China, said, "We see this program not just as an opportunity to help us discover new treatments but also a unique possibility for joint talent development." He added that the partners also are evaluating the establishment of a joint post doctorate program, which would pave the way for further enhancing scientific leadership and strengthen scientific interactions between the industry and academia.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing